May 27, 2023

. A successful new collaboration between Pfizer and BioNTech is announced. And all for a vaccine that can change the fate of many patients. BioNTech and Pfizer first collaborated in the field of infectious diseases in 2018, when they teamed up to develop a messenger RNA-based influenza vaccine. But they gained notoriety only with their second successful collaboration, which brought the first messenger RNA-based COVID-19 vaccine to market and received emergency use approval in December 2020. You might also be interested in: How long does alcohol stay in the body after drinking… Pfizer is preparing a new strike. Pfizer and BioNTech aim to develop an improved vaccine for an infectious disease using messenger RNA-based serum technology, the site reports Bioprocessintl . Pfizer and BioNTech are developing a vaccine for shingles Now, the two companies have teamed up again to produce a vaccine for shingles (herpes zoster). What is shingles and how many people does it affect? Shingles is a chronic form of the varicella zoster virus (VZV), which affects about one in three people in the US during their lifetime. The infection can cause an extremely painful rash, and in rare conditions can lead to deafness, blindness, and even facial paralysis. You might also be interested in: These are the benefits of eating chicken… “The collaboration aims to develop a new mRNA-based vaccine against zoster, leveraging the expertise and resources of both companies,” said Ugur Sahin, CEO of BioNTech. “Adults age 50 and older, as well as vulnerable populations such as cancer patients, are at increased risk for shingles. Our goal is to develop an mRNA-based vaccine with a favorable safety profile and high efficacy that is at the same time more easily scalable to support global access,” he emphasized. You might also be interested in: Cardiologist: these are the foods most … How the research money will be divided Under the agreement, the two companies will share development costs, but BioNTech will receive an upfront payment of $225 million, plus another $75 million and an equity investment of $150 million. The German firm will also have the right to receive up to $200 million in future marketing and sales fees, and Pfizer will collect an upfront payment of $25 million from BioNTech for the use of its antigen sequences . You might also be interested in: The new population vaccination campaign in Italy… Pfizer and BioNTech want an improved vaccine Two vaccines have been approved so far to treat shingles, one from GlaxoSmithKline and one from Merck & Co. Zostavax. However, Pfizer and BioNTech say there is enough room in the market to develop an improved vaccine that has the potential to produce greater efficacy and better tolerability using mRNA technology The information presented in this website is informative and does not replace the medical diagnosis or the product leaflet. Any decision regarding your health should only be made after consulting your doctor.